

Special Issue

Next-Generation HIV Antiretroviral Therapy and Vaccine Candidates

Message from the Guest Editors

Despite many years of research, a successful vaccine or cure for HIV-1 remains among the highest priority areas of unmet need in infectious disease. The vaccine development path for the HIV-1 pathogen has been extremely challenging for different reasons, one of them being the pathogen's high antigenic variability and immune evasion. Its high mutation rate allows it to evade immune responses by modifying its target immunogens during the course of infection. Therefore, I would like to encourage the submission of papers to this Special Issue that focus on novel approaches to vaccine development, including vaccine immunology, passive therapies, and genetic vaccination. Additionally, results from ongoing human vaccine clinical trials will also be integrated into this Special Issue. Moreover, being focused on a cure for HIV will address the problem of viral latency and how it is controlled and will emphasize cure-related human clinical trials.

Guest Editors

Dr. H.M. Manukumar

Institute of Human Virology, University of Maryland, Baltimore, MD 21201, USA

Prof. Tomas Hanke

1. Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford OX1 2JD, UK

2. International Research Center of Medical Sciences (IRCMS), Kumamoto University, Kumamoto 860-8555, Japan

Deadline for manuscript submissions

closed (31 March 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/65428

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).